Clinical Trial

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).

Study acronym: ELEV8
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated March 27, 2026 completion). Its status may not reflect the trial's current state.
Summary
This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration. Retinal fluid dynamics assessed by optical coherence tomography and changes in best-corrected visual acuity two months after baseline are analyzed to characterize early treatment outcomes.
Trial Details
NCT Number NCT07434713
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Age-Related Macular Degeneration (AMD)
Enrollment 50 participants
Start Date 2025-07-14
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-03-27 (estimated)
Updated on ClinicalTrials.gov 2026-02-27